Can-Fite: FDA Grants IND Clearance for Namodenoson to Treat Patients with MASH in Phase IIb Study
RAMAT GAN, Israel, May 9, 2024–(BUSINESS WIRE)–Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CANF), a biotechnology company advancing a portfolio of proprietary small molecule drugs that treat oncology and inflammatory diseases, …